Compounds > disulfiram

disulfiram and docetaxel anhydrous

disulfiram has been researched along with docetaxel anhydrous in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Budman, DR; Calabro, A1
Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W1
Chowdhury, R; Roy, A; Sharma, S; Swetha, KL1
Biswas, S; Kumbham, S; Maravajjala, KS; Paul, M; Roy, A; Swetha, KL1

Reviews

1 review(s) available for disulfiram and docetaxel anhydrous

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for disulfiram and docetaxel anhydrous

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
    Breast cancer research and treatment, 2002, Volume: 74, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2002
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
    British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfiram; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids

2013
Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Disulfiram; Docetaxel; Drug Synergism; Female; Humans; MCF-7 Cells; Reactive Oxygen Species

2020
Overcoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 356

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disulfiram; Docetaxel; Drug Resistance, Multiple; Hydrogen-Ion Concentration; Mice; Nanoparticles

2023